Intelligence · Clinical Development
Pipeline search results
Programs matching “breast-cancer” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 272 pipeline programs matching "breast-cancer" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Neratinib
PUMA BIOTECHNOLOGY, INC.
Triple Negative Breast Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Breast Cancer
8 trials -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Advanced Breast Cancer
1 trial -
Olaparib Continuous (28-Day cycle) 300 mg BD.
AstraZeneca
Metastatic Triple Negative Breast Cancer
1 trial -
Onapristone
Context Therapeutics
ER-positive Breast Cancer
1 trial -
Onvansertib
Cardiff Oncology
Breast Cancer
1 trial -
Organoid-guided treatment
The First People's Hospital of Lianyungang
HER2-negative Breast Cancer
1 trial -
PARP inhibitor 2X-121
Allarity Therapeutics
Metastatic Breast Cancer
1 trial -
PCS6422 and capecitabine
Processa Pharmaceuticals
Breast Cancer
1 trial -
PD 0332991
Pfizer
Breast Cancer
1 trial -
Paclitaxel
ONCOLYTICS BIOTECH INC
Metastatic Breast Cancer
1 trial -
Paclitaxel
PUMA BIOTECHNOLOGY, INC.
Breast Cancer
1 trial -
Paclitaxel
ONCOLYTICS BIOTECH INC
Breast Cancer Metastatic
1 trial -
Palbociclib 125Mg Tab
United Therapeutics Europe Ltd
ER+ Breast Cancer
1 trial -
Pelareorep
ONCOLYTICS BIOTECH INC
Anatomic Stage IV Breast Cancer AJCC v8
1 trial -
Pembrolizumab
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
Pembrolizumab
United Therapeutics Europe Ltd
Triple Negative Breast Cancer
1 trial -
Pembrolizumab
Inhibrx Biosciences
Triple Negative Breast Cancer
1 trial -
Pembrolizumab (200mg IV for 30 minutes
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
Placebo
NovaBridge Biosciences
Breast Cancer
1 trial -
Placebo
Cardiff Oncology
Metastatic Breast Cancer
1 trial -
Pyrotinib
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Radiotherapy Combined with Anlotinib and a Microtubule Inhibitor
The First People's Hospital of Lianyungang
HER2-Negative Breast Cancer
1 trial -
SG+I
Xiyuan Hospital of China Academy of Chinese Medical Sciences
TNBC, Triple Negative Breast Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.